At a glance
ClinicalIndex Comparison RecordN/ACompleted· 41 enrolled
Drug / intervention
EDOF ICLdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter Clinical Evaluation of the Clinical Performance of a Phakic Intraocular Lens
In Brief
A clinical study evaluating EDOF ICL for Presbyopia. Completed, enrolled 41 participants across 6 sites in 2 countries.
Detailed Summary
This study will evaluate the clinical performance of a phakic intraocular lens (IOL) for the improvement of Uncorrected Near Visual Acuity (UCNVA) in subjects who require between +1.00 and +2.50 Reading Add.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPresbyopia
CountriesBelgium, Spain
Collaborators--
Timeline
N/ACompletedFinished
201820192020202120222023202420252026
Enrollment StartMar 2018
First PostedApr 2018
Primary CompletionJul 2019
TodayJul 2026
First PostedApr 17, 2018
Enrollment StartMar 20, 2018
Primary CompletionJul 9, 2019
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 8.2 years ago
Interventions
EDOF ICLdevice
The Visian ICL is intended to be implanted within the posterior chamber, directly behind the iris, and in front of the anterior capsule of the human crystalline lens. It offers an intraocular alternative for the correction of refractive error in those who currently utilize spectacle and/or contact lenses correction.